玻璃体腔注射治疗不同病程两组特发性脉络膜新生血管病变

目的 对比分析Ranibizumab玻璃体腔注射治疗两组不同病程的特发性脉络膜新生血管病变患者(ICNV)的疗效。方法 经眼底荧光素血管造影(FFA)及光相干断层扫描(OCT)检查，并结合临床表现确诊为特发性脉络膜新生血管病变的患者36例36眼，按病程分为A(病程＜3个月)、B(3个月≤病程<6个月)两组。所有患者均行常规玻璃体腔ranibizumab注射治疗。治疗前检查两组受检者最佳矫正视力BCVA(logMAR)、屈光度、眼压、散瞳查眼底、光学相干断层扫描(OCT)检查病灶与中心凹的位置关系以及CMT、FFA。治疗后每月检查两组受检者BCVA(logMAR)、眼压、散瞳查眼底、OCT查CMT,必要时重复造影确定是否需要眼内重复注射。对比两组治疗前和治疗后1、3、6个月时的BCVA(logMAR)、CMT、眼压，并统计6个月时的注射次数。结果 与治疗前相比，两组在治疗后的1、3、6个月随访时，BCVA及CMT均有明显改善， P<0.05。而两组间在治疗后的1、3、6个月随访时， BCVA及CMT的比较差异无统计学意义(P>0.05),但至随访6个月时，A组的注射次数(1.3±0.5)次少于B组(2.1±1.2) 次(P＜0.05)。结论 玻璃体腔注射ranibizumab能够快速有效的改善ICNV患者病情，发病早期治疗可以减少注射次数，降低注射风险并减少治疗的成本。

Intravitreal injection of Ranibizumab for idiopathic choroidal neovascularization lesion in two courses

Objective To compare the effect of Ranibizumab by intravitreal injection for idiopathic choroidal neovascularization lesions (ICNV). Methods By fundus fluorescein angiography (FFA), optical coherence tomography (OCT) examination and clinical manifestation diagnosis, 36 patients(36 cases) were diagnosed as idiopathic choroidal neovascular lesions, and based on the course they were divided into group A (duration <3 months ) and B (3 months ≤ duration <6 months) . All patients underwent routine intravitreal Ranibizumab injections. The BCVA (logMAR), refraction, intraocular pressure and dilated fundus investigation were determined. Optical coherence tomography (OCT) was used to check the positional relationship between the lesion and the fovea and to measure CMT and FFA. Results In comparison with before treatment, BCVA and CMT were significantly improved at 3 and 6 months after treatment (P<0.05). While on the 1, 3 and 6 months after treatment, BCVA and CMT showed no significant difference between the two groups (P>0.05), but on 6 months, the injection time in group A (1.3±0.5 times) was lower than that in group B (2.1±1.2 times) (P<0.05). Conclusion Intravitreal injection of Ranibizumab can quickly and effectively improve the patient condition. The earlier the treatment, the lower the injection time, the risk and the cost.